JP2009508822A - 慢性腎症の処置のためのｈ因子およびその製造 - Google Patents
慢性腎症の処置のためのｈ因子およびその製造 Download PDFInfo
- Publication number
- JP2009508822A JP2009508822A JP2008530342A JP2008530342A JP2009508822A JP 2009508822 A JP2009508822 A JP 2009508822A JP 2008530342 A JP2008530342 A JP 2008530342A JP 2008530342 A JP2008530342 A JP 2008530342A JP 2009508822 A JP2009508822 A JP 2009508822A
- Authority
- JP
- Japan
- Prior art keywords
- factor
- functional
- treatment
- plasma
- functional factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010053085 Complement Factor H Proteins 0.000 title claims abstract description 117
- 102000016550 Complement Factor H Human genes 0.000 title claims abstract description 116
- 230000001684 chronic effect Effects 0.000 title claims abstract description 19
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 201000001474 proteinuria Diseases 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000000746 purification Methods 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 20
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 10
- 230000036470 plasma concentration Effects 0.000 claims description 10
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000007849 functional defect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000000543 intermediate Substances 0.000 claims 3
- 102000004411 Antithrombin III Human genes 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 229960005348 antithrombin iii Drugs 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- 210000002381 plasma Anatomy 0.000 description 16
- 230000027455 binding Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 230000024203 complement activation Effects 0.000 description 10
- 230000004154 complement system Effects 0.000 description 10
- 230000001434 glomerular Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 210000004926 tubular epithelial cell Anatomy 0.000 description 7
- 101150074155 DHFR gene Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 description 5
- 239000004019 antithrombin Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000000585 glomerular basement membrane Anatomy 0.000 description 5
- 102000045512 human CFH Human genes 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 4
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 4
- 102100030886 Complement receptor type 1 Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002206 pro-fibrotic effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NEEVCWPRIZJJRJ-LWRDCAMISA-N 5-(benzylideneamino)-6-[(e)-benzylideneamino]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound C=1C=CC=CC=1C=NC=1C(=O)NC(=S)NC=1\N=C\C1=CC=CC=C1 NEEVCWPRIZJJRJ-LWRDCAMISA-N 0.000 description 2
- 208000024985 Alport syndrome Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108700017374 Complement Factor H Deficiency Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 210000005086 glomerual capillary Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000003215 hereditary nephritis Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100031609 Complement C2 Human genes 0.000 description 1
- 108090000955 Complement C2 Proteins 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 102000050019 Membrane Cofactor Human genes 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710127332 Protease I Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000022401 dense deposit disease Diseases 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000001282 glomerular podocyte Anatomy 0.000 description 1
- 208000022182 gross hematuria Diseases 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000013462 industrial intermediate Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020409 | 2005-09-19 | ||
| PCT/EP2006/005631 WO2007038995A1 (en) | 2005-09-19 | 2006-06-13 | Factor h for the treatment of chronic nephropathies and production thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116143A Division JP2012184251A (ja) | 2005-09-19 | 2012-05-22 | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508822A true JP2009508822A (ja) | 2009-03-05 |
| JP2009508822A5 JP2009508822A5 (enExample) | 2009-06-25 |
Family
ID=36001069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530342A Pending JP2009508822A (ja) | 2005-09-19 | 2006-06-13 | 慢性腎症の処置のためのｈ因子およびその製造 |
| JP2012116143A Pending JP2012184251A (ja) | 2005-09-19 | 2012-05-22 | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116143A Pending JP2012184251A (ja) | 2005-09-19 | 2012-05-22 | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090118163A1 (enExample) |
| EP (1) | EP1928483B1 (enExample) |
| JP (2) | JP2009508822A (enExample) |
| KR (1) | KR20080048034A (enExample) |
| AU (1) | AU2006299293B2 (enExample) |
| CA (1) | CA2627264A1 (enExample) |
| WO (1) | WO2007038995A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014532401A (ja) * | 2011-10-25 | 2014-12-08 | ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | ヒトｈ因子の製造方法 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2894145B1 (fr) * | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
| EP2129686B1 (en) * | 2007-03-20 | 2016-07-13 | CSL Behring GmbH | Methods for industrial scale production of therapeutic complement factor h preparations from human plasma |
| AU2009313203B2 (en) * | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| GB0904427D0 (en) | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| WO2011011753A1 (en) * | 2009-07-23 | 2011-01-27 | Baxter International Inc. | Manufacture of factor h (fh) and fh-derivatives from plasma |
| FR2952640B1 (fr) | 2009-11-16 | 2012-12-07 | Lab Francais Du Fractionnement | Procede de fabrication d'une preparation de facteur h |
| FR2952539B1 (fr) | 2009-11-16 | 2012-01-13 | Lab Francais Du Fractionnement | Preparation d'un concentre de facteur h |
| GB0922659D0 (en) | 2009-12-24 | 2010-02-10 | Univ Edinburgh | Factor H |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| JP6092776B2 (ja) | 2010-09-15 | 2017-03-08 | セルデックス セラピューティクス インコーポレイテッド | 可溶性補体受容体Ｉ型（ｓＣＲ１）を用いる慢性腎症の処置 |
| RU2013121589A (ru) * | 2010-10-13 | 2014-11-20 | Октафарма Аг | Способ очистки фактора комплемента н |
| FR2983212A1 (fr) | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| AU2013203048A1 (en) | 2013-03-15 | 2014-10-02 | Baxalta GmbH | Isolation of factor h from fraction i paste |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| US20150079613A1 (en) | 2013-08-07 | 2015-03-19 | Ryan Kitchel | Atypical hemolytic uremic syndrome biomarker proteins |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62201822A (ja) * | 1985-11-08 | 1987-09-05 | Sankyo Co Ltd | 自己免疫性疾病の予防・治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
-
2006
- 2006-06-13 JP JP2008530342A patent/JP2009508822A/ja active Pending
- 2006-06-13 WO PCT/EP2006/005631 patent/WO2007038995A1/en not_active Ceased
- 2006-06-13 KR KR1020087006719A patent/KR20080048034A/ko not_active Ceased
- 2006-06-13 EP EP06754313.2A patent/EP1928483B1/en not_active Not-in-force
- 2006-06-13 AU AU2006299293A patent/AU2006299293B2/en not_active Ceased
- 2006-06-13 CA CA002627264A patent/CA2627264A1/en not_active Abandoned
- 2006-06-13 US US11/992,194 patent/US20090118163A1/en not_active Abandoned
-
2010
- 2010-11-01 US US12/916,807 patent/US10137165B2/en active Active
-
2012
- 2012-05-22 JP JP2012116143A patent/JP2012184251A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62201822A (ja) * | 1985-11-08 | 1987-09-05 | Sankyo Co Ltd | 自己免疫性疾病の予防・治療剤 |
Non-Patent Citations (3)
| Title |
|---|
| JPN5008012520; ＬＩＣＨＴ Ｃ: ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＫＩＤＮＥＹ ＤＩＳＥＡＳＥＳ Ｖ４５ Ｎ２, 200502, Ｐ４１５-４２１ * |
| JPN5008012521; ＨＯＧＡＳＥＮ ＫＯＬＢＪＯＲＮ: ＭＯＬＥＣＵＬＡＲ ＩＭＭＵＮＯＬＯＧＹ Ｖ３６ Ｎ４-５, 199903, Ｐ３０５， ＡＢＳＴＲＡＣＴ １０４ * |
| JPN5008012522; ＨＯＧＡＳＥＮ ＫＯＬＢＪＯＲＮ: ＪＯＵＲＮＡＬ ＯＦ ＴＨＥ ＡＭＥＲＩＣＡＮ ＳＯＣＩＥＴＹ ＯＦ ＮＥＰＨＲＯＬＯＧＹ Ｖ９, 199709, Ｐ４７４Ａ-４７５Ａ， ＡＢＳＴＲＡＣＴ Ａ２２０６ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014532401A (ja) * | 2011-10-25 | 2014-12-08 | ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | ヒトｈ因子の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090118163A1 (en) | 2009-05-07 |
| WO2007038995A1 (en) | 2007-04-12 |
| JP2012184251A (ja) | 2012-09-27 |
| EP1928483B1 (en) | 2016-12-28 |
| CA2627264A1 (en) | 2007-04-12 |
| AU2006299293A1 (en) | 2007-04-12 |
| KR20080048034A (ko) | 2008-05-30 |
| EP1928483A1 (en) | 2008-06-11 |
| US10137165B2 (en) | 2018-11-27 |
| US20110046062A1 (en) | 2011-02-24 |
| AU2006299293B2 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012184251A (ja) | 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用 | |
| RU2396347C2 (ru) | Модифицированные витамин к-зависимые полипептиды | |
| US6846649B1 (en) | Recombinant human mannan-binding lectin | |
| JP5049271B2 (ja) | 改変された活性化特性を有する第ｘ凝固因子ポリペプチド | |
| EP1991255B1 (en) | Coagulation factor x polypeptides with modified activation properties | |
| JP2020506693A (ja) | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 | |
| EP3453400B1 (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors | |
| CN106659771B (zh) | 修饰的von Willebrand因子 | |
| KR20250078598A (ko) | 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법 | |
| CA2649199C (en) | Method of increasing the in vivo recovery of therapeutic polypeptides | |
| CN108779165B (zh) | 突变的冯·维勒布兰德因子 | |
| TWI589594B (zh) | 用以治療和/或預防自體免疫疾病和發炎疾病的短合成胜肽 | |
| JP7604174B2 (ja) | 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物 | |
| JP2019187427A (ja) | Ｕｔｉ融合タンパク質 | |
| JPWO2016104436A1 (ja) | サイトカインストーム抑制剤 | |
| JP2024539242A (ja) | 慢性腎疾患の治療のための改変カベオリン－１ペプチド | |
| US20150366952A1 (en) | Methods for reducing fibrosis induced by peritoneal dialysis | |
| US20250177571A1 (en) | Sequence of activated protein c | |
| WO2008059917A1 (en) | Thrombin mutant | |
| JP2007532486A (ja) | 組織因子経路インヒビターの投与による重度の市中肺炎の処置 | |
| HK40004111B (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090430 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090430 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120522 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20120629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120629 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121113 |